entertainment -WSS

entertainment

author：leisure time 2025-09-27 10:03:47 - browse：98615

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Diversity in clinical trials starts with building trust, experts say

WSS

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Study finds gene variants tied to breast cancer risk in Black women

Getting Alzheimer's drug Leqembi to patients can be a challenge

Cancer researcher Catriona Jamieson is sending tumors into space

Diversity in clinical trials starts with building trust, experts say

At flashy new research hub, AstraZeneca lays out ambitious growth goals

explore

entertainment

leisure time

Hollywood unions extend contract negotiations for actors

Cell therapy fails to slow type 1 diabetes, but safety is established

Novavax promises a turnaround & Lilly roils the obesity market

MassMutual is introducing free genetic testing for members

The high cost of giving birth even with insurance

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Medicare details structure of new drug price negotiation program

Eyeing GLP

BioMarin wins approval for gene therapy to treat hemophilia A

H5N1 bird flu virus started spreading in cows in Texas in December

explore

FDA poised to publish guidelines for clinical trial diversity

Investigation reveals sickle cell patients pressured into sterilizations

H5N1 virus can be tracked in retail milk, scientists say

UnitedHealth argues against case alleging wrongful AI care denials

UnitedHealth argues against case alleging wrongful AI care denials

Eyeing GLP

Wikipedia

knowledge

knowledge

hotspot